Ravi Vij, MD, MBA

Bone Marrow Transplant Specialist, Medical Oncologist, Oncology

ravi vij

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Video thumbnail for Ravi Vij, MD

Watch video on YouTube

Ravi Vij, MD

2 mins

Washington University bone marrow transplant specialist and medical oncologist Ravi Vij, MD, discusses what patients with multiple myeloma, leukemia, myelodysplastic syndrome and stem-cell transplantation can expect from their extended care team at Siteman Cancer Center. Learn more about Dr. Vij: https://siteman.wustl.edu/doctor/vij-ravi/

Explore the Blood and Marrow Transplant Program at Siteman Cancer Center: https://siteman.wustl.edu/treatment/specialized-programs/stem-cell-transplant-and-cellular-therapies-center/blood-and-marrow-transplant-program/

Researchers at Washington University School of Medicine have developed a method for stem cell transplantation that doesn't require radiation or chemotherapy. Learn more: https://siteman.wustl.edu/new-technique-may-lead-to-safer-stem-cell-transplants/

Interested in becoming a donor? Learn more: https://siteman.wustl.edu/treatment/specialized-programs/stem-cell-transplant-and-cellular-therapies-center/blood-and-marrow-transplant-program/for-donors/

Clinical Expertise

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Board Certification

  • 1996: American Board of Internal Medicine, Internal Medicine
  • 1999: American Board of Internal Medicine, Medical Oncology
  • 2000: American Board of Internal Medicine, Hematology

Education

  • 1989: MBBS, Maulana Azad Medical College, New Delhi, India

Research & Selected Publications

Research Interest

Clinical interest in stem-cell transplantation and the management of hematologic malignancy. I lead a multi-disciplinary research program focused on treatment of multiple myeloma.

Research Publications

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma
Authors:

Ohlstrom DJ, Pilcher WC, Michaud ME, one or more additional authors omitted Vij R, one or more additional authors omitted Bhasin MK

Journal & Year:

Blood Cancer Discov | 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma
Authors:

Pilcher WC, Yao L, Gonzalez-Kozlova E, one or more additional authors omitted Vij R, one or more additional authors omitted Bhasin M

Journal & Year:

Nat Cancer | 2026

Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Authors:

Slade MJ, Fortier J, Khaled A, one or more additional authors omitted Vij R

Journal & Year:

Clin Lymphoma Myeloma Leuk | 2025

Chemo-RaST with bortezomib inhibits multiple myeloma relapse
Authors:

Ghai A, Zheleznyak A, Egbulefu C, one or more additional authors omitted Vij R, one or more additional authors omitted Achilefu S

Journal & Year:

Theranostics | 2025

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
Authors:

Ailawadhi S, Arnulf B, Patel K, one or more additional authors omitted Vij R, one or more additional authors omitted Rodríguez-Otero P

Journal & Year:

Blood | 2024

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma
Authors:

Sun J, Corradini S, Azab F, one or more additional authors omitted Vij R, one or more additional authors omitted Azab AK

Journal & Year:

Leukemia | 2024

A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Authors:

Goldsmith SR, Slade MJ, Fiala M, one or more additional authors omitted Vij R

Journal & Year:

Ann Hematol | 2024

Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial
Authors:

Richard S, Lesokhin AM, Paul B, one or more additional authors omitted Vij R, one or more additional authors omitted Dhodapkar MV

Journal & Year:

Nat Cancer | 2024